At 45.3 months' minimum follow-up:

Overall survival (OS) of Opdualag vs nivolumab
 

Reference: 

1. Data on file. BMS-REF-Nivo+Rela-0024. Princeton, NJ: Bristol-Myers Squibb Company; 2025.

At 45.3 months' minimum follow-up:
Opdualag vs nivolumab PFS, OS and ORR by subgroups^* 
 

^*ITT-population. EU approved indication: PD-L1 <1%.

^aMeasurements shown are the sums of the reference diameters of the target lesions. bM1 HR and 95% CI were not calculated due to small patient numbers.

PFS = progression free survival; OS = overall survival; ORR = objective response rate

1. Lipson, Evan J. et al. Nivolumab Plus Relatlimab in Advanced Melanoma: Supplementary material to RELATIVITY-047 4-year update. European Journal of Cancer, Volume 0, Issue 0, 115547.